Trans Tasman Radiation Oncology Group

Recent papers from Trans Tasman Radiation Oncology Group

1. ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerJournal of Clinical Oncology · 2026
2. Prophylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta‐AnalysisJournal of Medical Imaging and Radiation Oncology · 2026
3. Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CESMO Open · 2026
4. A novel blood biomarker for plastic ingestion in fledgling procellariiform seabirdsEnvironmental Research · 2026
5. Emerging Outcome Trends from Proton Therapy for Paediatric CNS Tumours: A Systematic ReviewInternational Journal of Particle Therapy · 2026
6. Low and steady: Minimal change in plastic exposure in Kermadec Petrels in the remote South PacificMarine Pollution Bulletin · 2026
7. No evidence of sex differences in plastic ingestion by Sable Shearwater (Ardenna carneipes) chicksMarine Pollution Bulletin · 2026
8. Clinical Trial Credentialing for Stereotactic Radiosurgery and Radiotherapy of Brain Metastases: Recommendations From the TROG SRS Technical Working GroupJournal of Medical Imaging and Radiation Oncology · 2026
9. Ctni-25. Multi-Site, Prospective Trial Evaluating Fet-Pet in Glioblastoma (Fig) Study (Trog 18.06): Central Nuclear Medicine and Radiation Oncology Review of Fet-Pet Biologic Target Volume Delineation for Radiation PlanningNeuro-Oncology · 2025
10. Nivolumab for Resected Stage III or IV Melanoma at 9 YearsNew England Journal of Medicine · 2025
11. Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerNature Communications · 2025
12. A proof of concept for improving comparability of dosimetry audits through centralised planningPhysics and Imaging in Radiation Oncology · 2025
13. Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial – protocol for a phase II studyBMJ Open · 2025
14. 148P Time toxicity and its relationship with quality of life in patients undergoing phase I cancer clinical trialsESMO Open · 2025
15. ‘Every Touch Point Is an Opportunity’: Tobacco Control Experts' Views on How to Implement Smoking Cessation Interventions Within an Australian Lung Cancer Screening ProgramCancer Medicine · 2025
16. Strength in numbers: Combining small pockets of opportunistic sampling for Australian seabird plastic ingestionMarine Pollution Bulletin · 2025
17. Experience with remote electronic portal imaging device-based dosimetric auditing for static and rotational intensity modulated radiotherapyPhysics and Imaging in Radiation Oncology · 2024
18. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 StudyJTO Clinical and Research Reports · 2024
19. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Journal of Clinical Oncology · 2024
20. Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinomaClinical Cancer Research · 2024